Because proteasome inhibitors are already used in the clinic to treat multiple myeloma [107, 108], it is possible that these inhibitors might prove being beneficial in breast cancers patients, whose tumors highly express FOXM1. The gene discussed is FOXM1; the disease is breast carcinoma.